CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward.
Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March:
- TD Cowen 45th Annual Health Care Conference
Format: Fireside Chat
Date: Monday, March 3
Time: 2:30 p.m. ET
Location: Boston, MA
- Leerink Partners Global Healthcare Conference
Format: Fireside Chat
Date: Monday, March 10
Time: 9:20 a.m. ET
Location: Miami, FL
- Barclays 27th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, March 11
Time: 9:00 a.m. ET
Location: Miami, FL
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
CONTACT: Media and Investor Contact:
ir@editasmed.com
